These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1103 related items for PubMed ID: 24935990

  • 1. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [Abstract] [Full Text] [Related]

  • 2. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 4. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [Abstract] [Full Text] [Related]

  • 6. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, Castellucci P, Picchio M, Al-Nahhas A, Colletti PM, Marcolongo A, Rubello D.
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [Abstract] [Full Text] [Related]

  • 7. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
    Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ.
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
    [Abstract] [Full Text] [Related]

  • 8. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J, Even-Sapir E, Ben-Haim S, Saad A, Spieler B, Davidson T, Berger R, Weiss I, Appel S, Lawrence YR, Symon Z.
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [Abstract] [Full Text] [Related]

  • 9. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [Abstract] [Full Text] [Related]

  • 10. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Ntreta M, Lodi F, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
    [Abstract] [Full Text] [Related]

  • 11. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [Abstract] [Full Text] [Related]

  • 12. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L, Schindler C, Montorsi F, Messa C, Fazio F.
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [Abstract] [Full Text] [Related]

  • 13. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic performance of 18F-choline PET-CT in prostate cancer.
    Samper Ots P, Luis Cardo A, Vallejo Ocaña C, Cabeza Rodríguez MA, Glaria Enríquez LA, Couselo Paniagua ML, Olivera Vegas J.
    Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
    [Abstract] [Full Text] [Related]

  • 15. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
    Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, Brunocilla E, Fantini L, Costa S, Ferretti A, Colletti PM, Rubello D, Fanti S.
    Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
    [Abstract] [Full Text] [Related]

  • 16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 17. [11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma.
    Reske SN, Moritz S, Kull T.
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):430-9. PubMed ID: 23069922
    [Abstract] [Full Text] [Related]

  • 18. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [Abstract] [Full Text] [Related]

  • 19. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.
    Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F, Gianolli L, Messa C.
    J Urol; 2013 Jan; 189(1):105-10. PubMed ID: 23164385
    [Abstract] [Full Text] [Related]

  • 20. 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study.
    Ceci F, Schiavina R, Castellucci P, Brunocilla E, Fuccio C, Colletti PM, Ferretti A, Chondrogiannis S, Rubello D, Romagnoli D, Malizia C, Martorana G, Fanti S.
    Clin Nucl Med; 2013 Jul; 38(7):e279-82. PubMed ID: 23698461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.